

4 September 2015

The Manager Company Announcements Australian Securities Exchange Limited Via Electronic Lodgment

Dear Sir/Madam

#### PHARMAUST LIMITED (ASX: PAA) - SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

The Company gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Act**").

The Company has issued 62,500 Fully Paid Ordinary Shares ("**Shares**")and 8,500,000 Unlisted Options Ex \$0.008 Expiry 3/9/18 ("**Options**") in the capital of the Company as per the Appendix 3B lodged with the ASX today.

The Company advises that the securities were issued without disclosure to investors under Part 6D.2 of the Act. The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Act.

As at the date of this notice there is no information that is excluded information for the purposes of sections 708A(7) and (8) of the Act.

Yours sincerely,

Sam Wright Director & Company Secretary PharmAust Limited

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

#### New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

PHARMAUST LIMITED

ABN

35 094 006 023

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully Paid Ordinary Shares Unlisted Options

62,500 Fully Paid Ordinary Shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares

8,500,000 Unlisted Options

Unlisted Options Exercise Price \$0.008

Expiry Date 3 September 2018

<sup>+</sup> See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?</li> <li>If the additional securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	Shares – Yes Options - No (new stream of Option)
5	Issue price or consideration	62,500 shares at 2c cents per share
		In accordance with the PAA Employee Share Option Plan approved by shareholders at the AGM held on 24 October 2014, and having noted that all the conditions precedent to the issue of the Options have been fulfilled.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Conversion of options raising \$1,250 for the Company In accordance with the PAA Employee Share Option Plan approved by shareholders at the AGM held on 24 October 2014, and having noted that all the conditions precedent to the issue of the Options have been fulfilled.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	24 October 2014
	-	

<sup>+</sup> See chapter 19 for defined terms.

- 6c Number of \*securities issued without security holder approval under rule 7.1
- 6d Number of \*securities issued with security holder approval under rule 7.1A
- 6e Number of \*securities issued Nil with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule Nil 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under Nil rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering \*securities into uncertificated holdings or despatch of certificates
- 8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in section 2 if applicable)

Nil			

Nil

Nil

Nil

See Annexure 1

4 September 2015	
Number	+Class
1,840,069,106	Fully Paid Ordinary Shares
8,500,000	Unlisted Options Ex \$0.008 Expiry 3/9/18

<sup>+</sup> See chapter 19 for defined terms.

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the securities in section 2 if applicable)

10	Dividend policy (in the case of a
	trust, distribution policy) on the
	increased capital (interests)

The Company does not expect to pay a dividend this period.

+Class

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non- renounceable?	N/A
13	Ratio in which the <sup>+</sup> securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has <sup>+</sup> security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A

Number

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee	N/A
	or commission	
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the	N/A
_)	broker to the issue	
24	Amount of any handling fee payable to brokers who lodge	N/A
	acceptances or renunciations on	
	behalf of <sup>+</sup> security holders	
25	If the issue is contingent on	N/A
2 <u>5</u>	*security holders' approval, the	
	date of the meeting	
26	Data antitlement and accontance	
20	Date entitlement and acceptance form and prospectus or Product	N/A
	Disclosure Statement will be sent	
	to persons entitled	
27	If the entity has issued options,	N/A
,	and the terms entitle option	,
	holders to participate on exercise, the date on which notices will be	
	sent to option holders	
		Γ
28	Date rights trading will begin (if applicable)	N/A
	upplicubic)	
29	Date rights trading will end (if	N/A
	applicable)	
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through	N/A
	a broker?	
31	How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a	N/A
	broker and accept for the	
	balance?	

<sup>+</sup> See chapter 19 for defined terms.

32	How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of securities ( <i>tick one</i> )
(a)	Securities described in Part 1
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible

#### Entities that have ticked box 34(a)

securities

#### Additional securities forming a new class of securities

Tick to	indicate	you	are	providing	the	information	or
docume	ents						

35	If the <sup>+</sup> securities are <sup>+</sup> equity securities, the names of the 20 largest holders of the additional <sup>+</sup> securities, and the number and percentage of additional <sup>+</sup> securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional +securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38 Number of securities for which <sup>+</sup>quotation is sought Class of +securities for which 39 quotation is sought Do the <sup>+</sup>securities rank equally in 40 all respects from the date of allotment with an existing <sup>+</sup>class of quoted +securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they • participate for the next dividend, (in the case of a trust, distribution) interest or payment the extent to which they do not • rank equally, other than in relation to the next dividend, distribution interest or payment Reason for request for quotation 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in clause 38)

Number	+Class	

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

4 September 2015

Sign here: ......Date: .....Date: ..... (Director & Company Secretary)

Sam Wright
Print name:

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital					
Step 1: Calculate "A", the base fig capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,656,006,606				
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	184,062,500				
period "A"	1,840,069,106				

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	276,010,366	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	nil	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	276,010,366	
Note: number must be same as shown in Step 2		
Subtract "C"	nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	276,010,366	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1 Step 2: Calculate 10% of "A"	1,840,069,106	
"D"	0.10 Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	184,006,911	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	184,006,911	
<i>Subtract</i> "E" <i>Note: number must be same as shown in</i> <i>Step 3</i>	Nil	
<i>Total</i> ["A" x 0.10] – "E"	184,006,911 Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.